TD Cowen Issues Positive Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price

Myriad Genetics (NASDAQ:MYGN) had its price target hoisted by TD Cowen from $4.50 to $6.75 in a research note published on Thursday,Benzinga reports. TD Cowen currently has a hold rating on the stock.

A number of other brokerages have also recently issued reports on MYGN. Piper Sandler raised shares of Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 price objective for the company in a research note on Tuesday, October 20th. Wall Street Zen downgraded shares of Myriad Genetics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Craig Hallum increased their price objective on shares of Myriad Genetics from $4.00 to $8.00 and gave the company a “buy” rating in a report on Friday, October 2nd. UBS Group assumed coverage on Myriad Genetics in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $3.60 target price on the stock. Finally, Stephens cut their price target on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.55.

Myriad Genetics Stock Up 4.5%

Myriad Genetics stock opened at $6.29 on Thursday. The stock has a market cap of $601.64 million, a PE ratio of -4.62 and a beta of 1.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. The stock has a fifty day moving average of $4.45 and a 200 day moving average of $4.62. Myriad Genetics has a one year low of $2.74 and a one year high of $8.09.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative net margin of 16.07% and a negative return on equity of 18.88%. The business had revenue of $202.70 million during the quarter, compared to analysts’ expectations of $191.33 million. As a group, sell-side analysts predict that Myriad Genetics will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds have recently added to or reduced their stakes in MYGN. Orbimed Advisors LLC bought a new position in Myriad Genetics in the 1st quarter valued at $562,500,000. BlackRock Inc. purchased a new position in Myriad Genetics during the 2nd quarter valued at about $62,184,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Myriad Genetics in the 2nd quarter worth approximately $8,039,000. Man Group plc bought a new position in Myriad Genetics in the second quarter worth approximately $5,189,000. Finally, Bank of America Corp DE bought a new stake in Myriad Genetics during the 2nd quarter valued at $5,150,000. 99.02% of the stock is currently owned by institutional investors.

Key Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Third-quarter revenue was $202.7 million, above the $191.3 million consensus estimate, while the loss of $0.11 per share was narrower than analysts’ expected $0.20 loss. Revenue rose 6% sequentially, supported by improved product mix and higher average revenue per test. Myriad Genetics Q3 2026 results and outlook
• Positive Sentiment: Myriad raised the midpoint of its full-year 2026 revenue guidance, outlining a $780 million–$790 million outlook following its agreement to sell its Prenatal Health business for $210 million. The company said the transaction will support strategic growth initiatives. Myriad revenue outlook and divestiture
• Neutral Sentiment: TD Cowen raised its price target to $6.75 from $4.50, retaining a Hold rating. Leerink Partners lifted its target to $8 from $5, while keeping a Market Perform rating. The higher targets reflect improved estimates, but both firms maintained non-buy ratings. TD Cowen rating Leerink Partners rating
• Negative Sentiment: Myriad disclosed that it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. The potential exposure and any operational or regulatory consequences remain unclear. Cybersecurity incident report

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.